Transcriptional role of p53 in interferon-mediated antiviral immunity

Journal of Experimental Medicine

Volumn 205, Issue 8, 2008, Pages 1929-1938

  Muñoz Fontela, César ^a   Macip, Salvador ^a,c   Martínez Sobrido, Luis ^a   Brown, Lauren ^a   Ashour, Joseph ^a   García Sastre, Adolfo ^a   Lee, Sam W ^b   Aaronson, Stuart A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON REGULATORY FACTOR 9; INTERFERON STIMULATED GENE FACTOR 3; PROTEIN P53;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELLS, CULTURED; GENE TARGETING; GENES, P53; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNITY, NATURAL; INTERFERON-STIMULATED GENE FACTOR 3, GAMMA SUBUNIT; INTERFERONS; MICE; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; VESICULAR STOMATITIS INDIANA VIRUS; VIRUS REPLICATION;

EID: 49249135191     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20080383     Document Type: Article

References (36)

1. García-Sastre, A., and C.A. Biron. 2006. Type 1 interferons and the virus-host relationship: a lesson in détente. Science. 312:879-882.
2. Platanias, L.C., and E.N. Fish. 1999. Signaling pathways activated by interferons. Exp. Hematol. 27:1583-1592.
3. Stark, G.R., I.M. Kerr, B.R. Williams, R.H. Silverman, and R.D. Schreiber. 1998. How cells respond to interferons. Annu. Rev. Biochem. 67:227-264.
4. Takaoka, A., S. Hayakawa, H. Yanai, D. Stoiber, H. Negishi, H. Kikuchi, S. Sasaki, K. Imai, T. Shibue, K. Honda, and T. Taniguchi. 2003. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature. 424:516-523.
5. Fuster, J.J., S.M. Sanz-González, U.M. Moll, and V. Andrés. 2007. Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol. Med. 13:192-199.
6. Pampin, M., Y. Simonin, B. Blondel, Y. Percherancier, and M.K. Chelbi-Alix. 2006. Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense. J. Virol. 80:8582-8592.
7. Townsend, P.A., T.M. Scarabelli, S.M. Davidson, R.A. Knight, D.S. Latchman, and A. Stephanou. 2004. STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J. Biol. Chem. 279:5811-5820.
8. Ding, Y., J.F. Lee, H. Lu, M.H. Lee, and D.H. Yan. 2006. Interferon-inducible protein IFIXalpha1 functions as a negative regulator of HDM2. Mol. Cell. Biol. 26:1979-1996.
9. Muñoz-Fontela, C., M.A. Garcia, I. Garcia-Cao, M. Collado, J. Arroyo, M. Esteban, M. Serrano, and C. Rivas. 2005. Resistance to viral infection of super p53 mice. Oncogene. 24:3059-3062.
10. Mori, T., Y. Anazawa, M. Iiizumi, S. Fukuda, Y. Nakamura, and H. Arakawa. 2002. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene. 21:2914-2918.
11. Hummer, B.T., X.L. Li, and B.A. Hassel. 2001. Role for p53 in gene induction by double-stranded RNA. J. Virol. 75:7774-7777.
12. Caserta, T.M., A.N. Smith, A.D. Gultice, M.A. Reedy, and T.L. Brown. 2003. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis. 8:345-352.
13. Zhang, L., J. Yu, B.H. Park, K.W. Kinzler, and B. Vogelstein. 2000. Role of BAX in the apoptotic response to anticancer agents. Science. 290:989-992.
14. Sugrue, M.M., D.Y. Shin, S.W. Lee, and S.A. Aaronson. 1997. Wildtype p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc. Natl. Acad. Sci. USA. 94:9648-9653.
15. Macip, S., M. Igarashi, P. Berggren, J. Yu, S.W. Lee, and S.A. Aaronson. 2003. Influence of induced reactive oxygen species in p53-mediated cell fate decisions. Mol. Cell. Biol. 23:8576-8585.
16. Macip, S., M. Igarashi, L. Fang, A. Chen, Z.Q. Pan, S.W. Lee, and S.A. Aaronson. 2002. Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence. EMBO J. 21:2180-2188.
17. Johnston, M.D. 1981. The characteristics required for Sendai virus preparation to induce high levels of interferon in human lymphoblastoid cells. J. Gen. Virol. 56:175-184.
18. Park, M.S., A. García-Sastre, J.F. Cros, C.F. Basler, and P. Palese. 2003. Newcastle disease virus V protein is a determinant of host range restriction. J. Virol. 77:9522-9532.
19. Marié, I., J.E. Durbin, and D.E. Levy. 1998. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J. 17:6660-6669.
20. Sato, M., N. Hata, M. Asagiri, T. Nakaya, T. Taniguchi, and N. Tanaka. 1998. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett. 441:106-110.
21. Yoneyama, M., W. Suhara, Y. Fukuhara, M. Sato, K. Ozato, and T. Fujita. 1996. Autocrine amplification of type I interferon gene expression mediated by interferon stimulated gene factor 3 (ISGF3). J. Biochem. 120:160-169.
22. Bluyssen, A.R., J.E. Durbin, and D.E. Levy. 1996. ISGF3 gamma p48, a specificity switch for interferon activated transcription factors. Cytokine Growth Factor Rev. 7:11-17.
23. Müller, M., S. Wilder, D. Bannasch, D. Israeli, K. Lehlbach, M. Li-Weber, S.L. Friedman, P.R. Galle, W. Stremmel, M. Oren, and P.H. Krammer. 1998. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188: 2033-2045.
24. Wong, K.B., B.S. DeDecker, S.M. Freund, M.R. Proctor, M. Bycroft, and A.R. Fersht. 1999. Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc. Natl. Acad. Sci. USA. 96:8438-8442.
25. Ellis, C.N., M.B. Ellis, and W.S. Blakemore. 1987. Effect of adriamycin on heart mitochondrial DNA. Biochem. J. 245:309-312.
26. Yanai, H., H.M. Chen, T. Inuzuka, S. Kondo, T.W. Mak, A. Takaoka, K. Honda, and T. Taniguchi. 2007. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc. Natl. Acad. Sci. USA. 104:3402-3407.
27. Zhao, C., C. Denison, J.M. Huibregtse, S. Gygi, and R.M. Krug. 2005. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc. Natl. Acad. Sci. USA. 102:10200-10205.
28. Youlyouz-Marfak, I., N. Gachard, C. Le Clorennec, I. Najjar, F. Baran-Marszak, L. Reminieras, E. May, G.W. Bornkamm, R. Fagard, and J. Feuillard. 2008. Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Cell Death Differ. 15:376-385.
29. Dharel, N., N. Kato, R. Muroyama, H. Taniguchi, M. Otsuka, Y. Wang, A. Jazag, R.-X. Shao, J.-H. Chang, M.K. Adler, et al. 2008. Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus. Hepatology. 47:1136-1149.
30. Fang, L., M. Igarashi, J. Leung, M.M. Sugrue, S.W. Lee, and S.A. Aaronson. 1999. p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene. 18:2789-2797.
31. Ebert, O., K. Shinozaki, T.G. Huang, M.J. Savontaus, A. García-Sastre, and S.L. Woo. 2003. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res. 63:3605-3611.
32. Basler, C.F., A. Mikulasova, L. Martinez-Sobrido, J. Paragas, E. Mühlberger, M. Bray, H.D. Klenk, P. Palese, and A. García-Sastre. 2003. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 77:7945-7956.
33. Martínez-Sobrido, L., E.I. Zúñiga, D. Rosario, A. García-Sastre, and J.C. de la Torre. 2006. Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 80:9192-9199.
34. Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 108:193-199.
35. Kwak, J.C., P.P. Ongusaha, T. Ouchi, and S.W. Lee. 2003. IFI16 as a negative regulator in the regulation of p53 and p21(Waf1). J. Biol. Chem. 278:40899-40904.
36. Donehower, L.A., M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery Jr., J.S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:215-221.